<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03598218</url>
  </required_header>
  <id_info>
    <org_study_id>GLMU-03</org_study_id>
    <nct_id>NCT03598218</nct_id>
  </id_info>
  <brief_title>Hypofractionated Versus Conventionally Fractionated Radiotherapy for Initial Distant Metastases Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Multicenter, Prospective, Randomized, Phase II Trial Evaluating Hypofractionated Versus Conventionally Fractionated Radiotherapy for Initial Distant Metastases Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wei Jiang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wuzhou Red Cross Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangxi Naxishan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanning Monority Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Linshan pepole Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guilin Medical University, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiotherapy is an important treatment for initial distant metastases nasopharyngeal&#xD;
      carcinoma. Total dose and fraction size are important prognostic factors for survival,&#xD;
      although to our knowledge the optimal model has not been well determined to date. The purpose&#xD;
      of this clinical trial is to investigate the optimal radiation dose to investigate the&#xD;
      feasibility of decreasing the total dose and increasing the fraction size with the objective&#xD;
      of achieving a better balance between local control and severe late complications. for&#xD;
      initial distant metastases nasopharyngeal carcinoma with definitive radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine if hypofractionated with a smaller total dose radiation is not inferior to&#xD;
      standard-dose radiation in progression-free survival for initial distant metastases&#xD;
      nasopharyngeal carcinoma .&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate if hypofractionated with a low total dose radiation is not inferior to&#xD;
      standard-dose radiation in overall survival and locoregional failure-free survival for&#xD;
      initial distant metastases nasopharyngeal carcinoma II. To evaluate if hypofractionated with&#xD;
      a low total dose radiation with chemotherapy decrease treatment-related toxicities&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients are randomized to one of the two treatment arms&#xD;
&#xD;
      ARM 1: Patients receive hypofractionated with a low total dose radiation with induced&#xD;
      chemotherapy and adjuvant chemotherapy.Hypofractionated dose IMRT: GTVnx 60Gy, GTVnd 60Gy,&#xD;
      PTV1 50Gy and PTV2 45Gy in 25 fractions, 5 days/week.&#xD;
&#xD;
      Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 75mg/m2 D1(or D1-3), 3-week&#xD;
      chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel&#xD;
      135mg/m2 D1+Cisplatin 75mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles.&#xD;
&#xD;
      ARM 2: Patients receive standard-dose radiation with concurrent chemotherapy. Standard-dose&#xD;
      IMRT: GTVnx 69.69Gy, GTVnd 60-68Gy, PTV1 59.4Gy and PTV2 54Gy in 33 fractions, 5 days/week.&#xD;
&#xD;
      Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 75mg/m2 D1(or D1-3), 3-week&#xD;
      chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel&#xD;
      135mg/m2 D1+Cisplatin 75mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles.&#xD;
&#xD;
      After completion of study therapy, patients are followed up every 3-4 months for 2 years,&#xD;
      then every 6 months for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 13, 2018</start_date>
  <completion_date type="Anticipated">July 13, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 13, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>The time from the first day of therapy to locoregional relapse, distant relapse or tumor-related death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>The time from the first day of therapy to death or last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional relapse-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>The time from the first day of treatment to the time of first locoregional relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>The time from the first day of treatment to the time of first distant metastasis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Hypofractionated dose IMRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive hypofractionated with a low total dose radiation with induced chemotherapy and adjuvant chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard-dose IMRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive standard-dose radiation therapy with induced chemotherapy and adjuvant chemotherapy..</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofraction radiation</intervention_name>
    <description>Hypofractionated dose IMRT: GTVnx 60Gy, GTVnd 60Gy, PTV1 50Gy and PTV2 45Gy in 25 fractions, 5 days/week.&#xD;
Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles.</description>
    <arm_group_label>Hypofractionated dose IMRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard dose IMRT</intervention_name>
    <description>Standard dose IMRT: GTVnx 69.69Gy, GTVnd 60-68Gy, PTV1 54.9Gy and PTV2 54Gy in 33 fractions, 5 days/week.&#xD;
Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles.</description>
    <arm_group_label>Standard-dose IMRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with newly histologically confirmed non-keratinizing (according to WHO&#xD;
             histologically type) Tumor staged as any T or any N with M (according to the 8th AJCC&#xD;
             edition).&#xD;
&#xD;
          2. No pregnant female&#xD;
&#xD;
          3. Age between 18-70&#xD;
&#xD;
          4. Normal complete blood count level (hemoglobin &gt;10 g/dL, white blood cells ≥4000/μL,&#xD;
             platelets ≥100 000/μL)&#xD;
&#xD;
          5. Normal hepatic functions (serum total bilirubin ≤1.6 mg/dL, serum transminase &lt; 2.5&#xD;
             times higher than upper limit)&#xD;
&#xD;
          6. Normal renal function (serum creatinine ≤1.5 mg/dL, creatinine clearance ≥60 mL/min)&#xD;
&#xD;
          7. Karnofsky performance status (KPS) score of at least 70&#xD;
&#xD;
          8. Without radiotherapy or chemotherapy&#xD;
&#xD;
          9. Patients must give signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other or mixed pathological type&#xD;
&#xD;
          2. age &gt; 70 years or &lt;18 years&#xD;
&#xD;
          3. Prior chemotherapy, radiation, surgical resection or target therapy of the primary&#xD;
             tumor;&#xD;
&#xD;
          4. Significant medical or psychiatric illnesses that in the physician's judgment&#xD;
             (uncontrolled coronary heart disease, cardiomyopathy and/or heart failure requiring&#xD;
             hospitalization. Uncontrolled hypertension or history of myocardial infarction within&#xD;
             one year. Uncontrolled diabetes mellitus. Acute bacterial or fungal infection&#xD;
             requiring intravenous antibiotics;&#xD;
&#xD;
          5. Refused to sign informed consent form&#xD;
&#xD;
          6. Concurrent pregnancy or lactation&#xD;
&#xD;
          7. History of a second malignancy other than nasopharyngeal carcinoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Jiang, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Guilin Medical University, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rui Cai, M.D.</last_name>
    <phone>+86-773-2882906</phone>
    <email>33503706@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangxi Naxishan Hospital</name>
      <address>
        <city>Guilin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu-fei Pan, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linshan people's hospital</name>
      <address>
        <city>Linshan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-xin Su</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuzhou Red Cross Hospital</name>
      <address>
        <city>Wuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bin Zhang, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>July 14, 2018</study_first_submitted>
  <study_first_submitted_qc>July 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>July 14, 2018</last_update_submitted>
  <last_update_submitted_qc>July 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Guilin Medical University, China</investigator_affiliation>
    <investigator_full_name>Wei Jiang</investigator_full_name>
    <investigator_title>Wei Jiang, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Hypofractionated Radiation</keyword>
  <keyword>initial distant metastases</keyword>
  <keyword>nasopharyngeal carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

